share_log

德琪醫藥-B:2024 中期報告

ANTENGENE-B: 2024 INTERIM REPORT

HKEX ·  Sep 27 16:57

Summary by Moomoo AI

德琪醫藥有限公司(Antengene Corporation Limited)於2024年6月30日公佈中期財務報告,顯示期內收入為人民幣60,779千元,較去年同期的人民幣72,016千元下降15.6%。其他收入及收益由人民幣121,073千元大幅減少至人民幣27,317千元。研發成本從人民幣226,093千元降至人民幣130,841千元,銷售及分銷開支亦由人民幣88,246千元減少至人民幣56,028千元。期內虧損為人民幣167,033千元,較去年同期的人民幣218,694千元有所改善。公司於報告期內未派發任何股息。截至2024年6月30日,公司現金及銀行結餘為人民幣1,023,682千元。董事會已審閱中期財務報告,並與外部核數師安永會計師事務所進行了獨立審閱。
德琪醫藥有限公司(Antengene Corporation Limited)於2024年6月30日公佈中期財務報告,顯示期內收入為人民幣60,779千元,較去年同期的人民幣72,016千元下降15.6%。其他收入及收益由人民幣121,073千元大幅減少至人民幣27,317千元。研發成本從人民幣226,093千元降至人民幣130,841千元,銷售及分銷開支亦由人民幣88,246千元減少至人民幣56,028千元。期內虧損為人民幣167,033千元,較去年同期的人民幣218,694千元有所改善。公司於報告期內未派發任何股息。截至2024年6月30日,公司現金及銀行結餘為人民幣1,023,682千元。董事會已審閱中期財務報告,並與外部核數師安永會計師事務所進行了獨立審閱。
Antengene Corporation Limited announced its interim financial report as of June 30, 2024, revealing a revenue of RMB 60,779 thousand during the period, a decrease of 15.6% compared to RMB 72,016 thousand in the same period last year. Other income and gains significantly decreased from RMB 121,073 thousand to RMB 27,317 thousand. Research and development costs reduced from RMB 226,093 thousand to RMB 130,841 thousand, while sales and distribution expenses also decreased from RMB 88,246 thousand to RMB 56,028 thousand. The company incurred a loss of RMB 167,033 thousand during the period, showing an improvement compared to RMB 218,694 thousand in the same period last year. No dividends were distributed by the company during the reporting period. As of June 30, 2024, the company's cash and bank balances amounted to RMB 1,023,682 thousand. The board of directors has reviewed the interim financial report, which underwent independent review by the external auditor Ernst & Young CPA Ltd.
Antengene Corporation Limited announced its interim financial report as of June 30, 2024, revealing a revenue of RMB 60,779 thousand during the period, a decrease of 15.6% compared to RMB 72,016 thousand in the same period last year. Other income and gains significantly decreased from RMB 121,073 thousand to RMB 27,317 thousand. Research and development costs reduced from RMB 226,093 thousand to RMB 130,841 thousand, while sales and distribution expenses also decreased from RMB 88,246 thousand to RMB 56,028 thousand. The company incurred a loss of RMB 167,033 thousand during the period, showing an improvement compared to RMB 218,694 thousand in the same period last year. No dividends were distributed by the company during the reporting period. As of June 30, 2024, the company's cash and bank balances amounted to RMB 1,023,682 thousand. The board of directors has reviewed the interim financial report, which underwent independent review by the external auditor Ernst & Young CPA Ltd.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more